Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics Revenue

Protalix BioTherapeutics had revenue of $59.65M in the twelve months ending March 31, 2024, with 45.00% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $3.75M, a -60.91% decrease year-over-year. In the year 2023, Protalix BioTherapeutics had annual revenue of $65.49M with 37.48% growth.

• Revenue (ttm): $59.65M
• Revenue Growth: +45.00%
• P/S Ratio: 1.38
• Revenue / Employee: $286,798
• Employees: 208
• Market Cap: 82.11M USD

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	65.49M	17.86M	37.48%
Dec 31, 2022	47.64M	9.29M	24.22%
Dec 31, 2021	38.35M	-24.55M	-39.03%
Dec 31, 2020	62.90M	8.21M	15.00%
Dec 31, 2019	54.69M	20.45M	59.73%
Dec 31, 2018	34.24M	13.16M	62.44%
Dec 31, 2017	21.08M	11.88M	129.13%
Dec 31, 2016	9.20M	4.84M	110.79%
Dec 31, 2015	4.36M	841.00K	23.87%
Dec 31, 2014	3.52M	-	-
Dec 31, 2013	0	-	-
Dec 31, 2012	34.42M	31.46M	1,059.84%
Dec 31, 2011	2.97M	-8.28M	-73.60%
Dec 31, 2010	11.24M	10.86M	2,797.94%
Dec 31, 2009	388.00K	-	-
Dec 31, 2008	0	-	-
Dec 31, 2007	0	-	-
Dec 31, 2006	0	-	-
Dec 31, 2005	150.00K	-280.00K	-65.12%
Dec 31, 2004	430.00K	-	-
Dec 31, 2003	0	-	-
Dec 31, 2002	0	-	-
Dec 31, 2001	0	-	-
Dec 31, 2000	0	-	-
Dec 31, 1999	3.55M	-4.48M	-55.76%
Dec 31, 1998	8.04M	-	-
Dec 31, 1997	0	-	-
Nov 30, 1996	0	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.